Clinical Application of Drug Delivery Systems in Cancer Chemotherapy: Review of the Efficacy and Side Effects of Approved Drugs

Iwamoto, Takuya

doi:10.1248/bpb.b12-01102

Cited by 219 publications

(134 citation statements)

References 9 publications

(7 reference statements)

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…Mice bearing tumors between 10 mm 3 fluorescently labeled alginate strands conjugated to complementary ODNs were administered i.v. Imaging of mice first revealed that i.v.-administered alginate strands collected in the tumors of all mice at 24 h postadministration, presumably through the EPR effect ( Fig.…”

Section: Resultsmentioning

confidence: 99%

Refilling drug delivery depots through the blood

Brudno

Silva

Kearney

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Local drug delivery depots have significant clinical utility, but there is currently no noninvasive technique to refill these systems once their payload is exhausted. Inspired by the ability of nanotherapeutics to target specific tissues, we hypothesized that bloodborne drug payloads could be modified to home to and refill hydrogel drug delivery systems. To address this possibility, hydrogels were modified with oligodeoxynucleotides (ODNs) that provide a target for drug payloads in the form of free alginate strands carrying complementary ODNs. Coupling ODNs to alginate strands led to specific binding to complementary-ODN-carrying alginate gels in vitro and to injected gels in vivo. When coupled to a drug payload, sequencetargeted refilling of a delivery depot consisting of intratumor hydrogels completely abrogated tumor growth. These results suggest a new paradigm for nanotherapeutic drug delivery, and this concept is expected to have applications in refilling drug depots in cancer therapy, wound healing, and drug-eluting vascular grafts and stents.nanoparticle | targeting | DNA nanotechnology | controlled release | biomaterials

show abstract

Section: Resultsmentioning

confidence: 99%

Refilling drug delivery depots through the blood

Brudno

Silva

Kearney

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…Encapsulation drugs in liposomal nanoparticles show promising results in the clinical setting. Doxorubicin HCl liposomal injection (Doxil) was approved for the treatment of AIDS-related Kaposi's sarcoma (USA in 1995 and Japan in 2007), and for the treatment of ovarian cancer (USA in 1999 and Japan in 2009) after failure of prior systemic chemotherapy or intolerance or after failure of platinumbased chemotherapy [125] . In addition, in 2007 the FDA approved Doxil for the treatment of multiple myeloma in combination with bortezomib.…”

Section: Evading P-gp (Nanoparticle Drug Delivery Systems)mentioning

confidence: 99%

How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

Jaramillo¹,

Saig²,

Cloos³

et al. 2018

CDR

View full text Add to dashboard Cite

P-glycoprotein (ABCB1), multidrug resistance protein-1 (ABCC1) and breast cancer resistance protein (ABCG2) belong to the ATP-binding cassette (ABC) superfamily of proteins that play an important physiological role in protection of the body from toxic xenobiotics and endogenous metabolites. Beyond this, these transporters determine the toxicity profile of many drugs, and confer multidrug resistance (MDR) in cancer cells associated with a poor treatment outcome of cancer patients.It has long been hypothesized that inhibition of ABC drug efflux transporters will increase drug accumulation and thereby overcome MDR, but until now no approved inhibitor of these transporters is available in the clinic. In this review we present molecular strategies to overcome this type of drug resistance and discuss for each of these strategies their promising value or indicate underlying reasons for their limited success.

show abstract

“…24 Magnetic nanoparticle (MNP) drug delivery promises to be highly synergistic with MRgFUS. MNPs can be conjugated to chemotherapy and enriched in a targeted area by using a magnetic field generated by an external magnet to attract them, which is termed magnetic targeting (MT).…”

Section: Nanoparticle Conjugation and Mrgfusmentioning

confidence: 99%

A review of potential applications of MR-guided focused ultrasound for targeting brain tumor therapy

Lamsam¹,

Johnson²,

Connolly³

et al. 2018

Neurosurgical Focus

View full text Add to dashboard Cite

Magnetic resonance–guided focused ultrasound (MRgFUS) has been used extensively to ablate brain tissue in movement disorders, such as essential tremor. At a lower energy, MRgFUS can disrupt the blood-brain barrier (BBB) to allow passage of drugs. This focal disruption of the BBB can target systemic medications to specific portions of the brain, such as for brain tumors. Current methods to bypass the BBB are invasive, as the BBB is relatively impermeable to systemically delivered antineoplastic agents. Multiple healthy and brain tumor animal models have suggested that MRgFUS disrupts the BBB and focally increases the concentration of systemically delivered antitumor chemotherapy, immunotherapy, and gene therapy. In animal tumor models, combining MRgFUS with systemic drug delivery increases median survival times and delays tumor progression. Liposomes, modified microbubbles, and magnetic nanoparticles, combined with MRgFUS, more effectively deliver chemotherapy to brain tumors. MRgFUS has great potential to enhance brain tumor drug delivery, while limiting treatment toxicity to the healthy brain.

show abstract

Clinical Application of Drug Delivery Systems in Cancer Chemotherapy: Review of the Efficacy and Side Effects of Approved Drugs

Cited by 219 publications

References 9 publications

Refilling drug delivery depots through the blood

Refilling drug delivery depots through the blood

How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

A review of potential applications of MR-guided focused ultrasound for targeting brain tumor therapy

Contact Info

Product

Resources

About